SCHEMBL4077875

SCHEMBL4077875

CC(O)N(c1nc(N2CCCCC2)c2ncnc(N(C(C)O)C(C)O)c2n1)C(C)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 10/20 0.43
MAPT P10636 4/20 0.43
KDM4E B2RXH2 3/20 0.43
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
TSHR P16473 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
ALDH1A1 P00352 2/20 0.43
CYP2D6 P10635 2/20 0.43
CYP2C9 P11712 2/20 0.43
HPGD P15428 2/20 0.43
CYP2C19 P33261 2/20 0.43
MEN1 O00255 1/20 0.43
PDE2A O00408 1/20 0.43
RGS12 O14924 1/20 0.43
SLC22A2 O15244 1/20 0.43
SLC22A1 O15245 1/20 0.43
ABCC4 O15439 1/20 0.43
ABCC5 O15440 1/20 0.43
PDE6D O43924 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9565592 0.91 SLC29A1 (0.49) SLC29A1MAPTKDM4ELMNASMN1; SMN2
SCHEMBL15065643 0.85 SLC29A1 (0.48) SLC29A1MAPTKDM4ELMNASMN1; SMN2
SCHEMBL141541 0.84 SLC29A1 (0.54) SLC29A1MAPTKDM4ELMNASMN1; SMN2
SCHEMBL3395769 0.84 SLC29A1 (0.54) SLC29A1MAPTKDM4ELMNASMN1; SMN2
SCHEMBL11026413 0.82 SLC29A1 (0.41) SLC29A1MAPTKDM4ELMNASMN1; SMN2
SCHEMBL11023583 0.82 SLC29A1 (0.41) SLC29A1MAPTKDM4ELMNASMN1; SMN2
SCHEMBL1956785 0.79 SLC29A1 (0.41) SLC29A1MAPTKDM4ELMNASMN1; SMN2
SCHEMBL7446838 0.76 SLC29A1 (0.47) SLC29A1MAPTKDM4ELMNASMN1; SMN2
SCHEMBL10665575 0.76 HIF1A (0.34) MAPTKDM4ELMNASMN1; SMN2TSHR
SCHEMBL10663473 0.75 KDM4E (0.40) SLC29A1KDM4ELMNASMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2062580-A1 Use of dipyridamole or mopidamole for treatment and prevention of thromboembolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of trombin receptors Boehringer Ingelheim International GmbH (DE) 2009-05-27 EP disclosed